By Josh White
Date: Thursday 05 Jun 2025
(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using fruquintinib and sintilimab to treat advanced renal cell carcinoma in patients who have failed prior tyrosine kinase inhibitor treatment.
Grant of Share Options and Awards under LTIP | 10-Jun-2025 | 11:00 | RNS |
Total Voting Rights | 30-May-2025 | 09:30 | RNS |
AGM held on May 13, 2025 – Poll Results | 13-May-2025 | 11:45 | RNS |
2024 Annual Report and Notice of AGM | 07-Apr-2025 | 09:30 | RNS |
Extraordinary General Meeting – Poll Results | 31-Mar-2025 | 10:30 | RNS |
Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
Currency | UK Pounds |
Share Price | 219.00p |
Change Today | -1.00p |
% Change | -0.45 % |
52 Week High | 325.00 |
52 Week Low | 189.00 |
Volume | 144,324 |
Shares Issued | 871.61m |
Market Cap | £1,908.83m |
RiskGrade | 226 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:39 | 2,500 @ 219.00p |
16:39 | 2,500 @ 219.00p |
16:39 | 2,500 @ 219.00p |
16:39 | 2,500 @ 219.00p |
16:39 | 2,500 @ 219.00p |
You are here: research